| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LEXEO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Do | Lexeo Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Mo | Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 31.03. | Cantor Fitzgerald bestätigt "Übergewichten"-Rating für Lexeo Therapeutics | 7 | Investing.com Deutsch | ||
| 31.03. | Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating | 3 | Investing.com | ||
| 30.03. | Lexeo Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 30.03. | Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights | 171 | GlobeNewswire (Europe) | SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness... ► Artikel lesen | |
| 05.02. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.01. | Lexeo Therapeutics stellt Führungsteam neu auf und ernennt Chief Medical Officer | 1 | Investing.com Deutsch | ||
| 27.01. | Lexeo Therapeutics announces key leadership appointments | 1 | Investing.com | ||
| 27.01. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.01. | Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock | 9 | Investing.com | ||
| 13.01. | Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating | 1 | Investing.com | ||
| 13.01. | H.C. Wainwright lowers Lexeo Therapeutics stock price target on PKP2 data concerns | 3 | Investing.com | ||
| 12.01. | Aktie von Lexeo Therapeutics bricht nach Studiendaten zur Gentherapie ein | 5 | Investing.com Deutsch | ||
| 12.01. | Lexeo Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.01. | Lexeo: Positive Studiendaten zu Gentherapie bei Herzerkrankung | 3 | Investing.com Deutsch | ||
| 12.01. | Lexeo's gene therapy shows promising results for heart condition | 3 | Investing.com | ||
| 12.01. | Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy | 238 | GlobeNewswire (Europe) | LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, and increased protein expression observed across participants... ► Artikel lesen | |
| 08.01. | Lexeo Therapeutics Partners With JNJ To Investigate Localized Cardiac Delivery Of Gene Therapy | 474 | AFX News | NEW BRUNSWICK (dpa-AFX) - Lexeo Therapeutics, Inc. (LXEO), Thursday announced a research collaboration with Johnson & Johnson (JNJ) to investigate localized cardiac delivery of gene therapy.Under... ► Artikel lesen | |
| 08.01. | Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy | 246 | GlobeNewswire (Europe) | Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson's expertise in cardiovascular therapeutics and circulatory technologies, including Impella heart pumps... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 29,035 | +1,84 % | Prognoseschock bei Diagnostikspezialist sorgt für neue Unsicherheit: QIAGEN-Aktie unter Druck: Gewinnwarnung schürt Zweifel an Erholung | QIAGEN überrascht den Markt mit einer deutlichen Senkung der Jahresprognose für 2026. Die schwächelnde Nachfrage und zunehmende Unsicherheiten setzen den Diagnostikkonzern spürbar unter Druck.Gedämpfte... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,820 | +0,36 % | EQS-News: Heidelberg Pharma AG berichtet über die ersten drei Monate des Geschäftsjahres 2026 | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Zwischenbericht
Heidelberg Pharma AG berichtet über die ersten drei Monate des Geschäftsjahres 2026
29.04.2026 / 07:05 CET/CEST
Für... ► Artikel lesen | |
| ILLUMINA | 107,08 | -0,80 % | Illumina Q1 Profit Rises On Higher Revenue, Improved Margins | SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) on Thursday reported first-quarter results, with profit increasing from last year, driven by higher revenue and improved margins. Revenue for the quarter... ► Artikel lesen | |
| BRAIN BIOTECH | 2,750 | +0,73 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Patent
BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie
23.03.2026 / 11:05 CET/CEST
Für... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,102 | +0,39 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) | ||
| VIKING THERAPEUTICS | 25,600 | -3,58 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,746 | -0,82 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart, Inc.: Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET | ||
| IMMUNITYBIO | 6,130 | +1,32 % | IBRX: What Anktiva's Bladder Data Says About 2026 Sales | ||
| MICROBOT MEDICAL | 1,755 | -1,13 % | Microbot Medical Inc.: Microbot Medical Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA) | Commencement of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent Full Market Release in the U.S. Strong physician... ► Artikel lesen | |
| ATAIBECKLEY | 3,500 | -1,69 % | Psychedelika im Aufwind - AtaiBeckley und Emyria im Fokus | ||
| CARDIFF ONCOLOGY | 1,441 | -1,97 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| EMERGENT BIOSOLUTIONS | 6,775 | -3,49 % | Emergent BioSolutions Reports First Quarter 2026 Financial Results | First Quarter 2026 Total Revenues of $156.1 millionFirst Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4%First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA... ► Artikel lesen | |
| DENALI THERAPEUTICS | 16,035 | +0,60 % | What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in | ||
| TRAWS PHARMA | 1,480 | +3,50 % | Traws Pharma, Inc. - 10-K/A, Annual Report |